DK3280416T3 - Doseringsskema for manglende doser for langtids-virkende injicerbare paliperidonestere - Google Patents

Doseringsskema for manglende doser for langtids-virkende injicerbare paliperidonestere Download PDF

Info

Publication number
DK3280416T3
DK3280416T3 DK16777058.5T DK16777058T DK3280416T3 DK 3280416 T3 DK3280416 T3 DK 3280416T3 DK 16777058 T DK16777058 T DK 16777058T DK 3280416 T3 DK3280416 T3 DK 3280416T3
Authority
DK
Denmark
Prior art keywords
paliperid
easters
injective
lacking
doses
Prior art date
Application number
DK16777058.5T
Other languages
English (en)
Inventor
Srihari Gopal
Paulien Gerarda Maria Ravenstijn
Alberto Russu
Mahesh Narain Samtani
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57072843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3280416(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3280416T3 publication Critical patent/DK3280416T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK16777058.5T 2015-04-07 2016-03-30 Doseringsskema for manglende doser for langtids-virkende injicerbare paliperidonestere DK3280416T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144054P 2015-04-07 2015-04-07
US201562162596P 2015-05-15 2015-05-15
PCT/US2016/024841 WO2016164218A1 (en) 2015-04-07 2016-03-30 Dosing regimen for missed doses for long-acting injectable paliperidone esters

Publications (1)

Publication Number Publication Date
DK3280416T3 true DK3280416T3 (da) 2020-05-11

Family

ID=57072843

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20169861.0T DK3744326T3 (da) 2015-04-07 2016-03-30 Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere
DK16777058.5T DK3280416T3 (da) 2015-04-07 2016-03-30 Doseringsskema for manglende doser for langtids-virkende injicerbare paliperidonestere

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK20169861.0T DK3744326T3 (da) 2015-04-07 2016-03-30 Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere

Country Status (27)

Country Link
US (1) US10143693B2 (da)
EP (3) EP4349323A3 (da)
JP (3) JP6728221B2 (da)
KR (3) KR20250013293A (da)
AU (4) AU2016244801B2 (da)
BR (1) BR112017021383A2 (da)
CA (2) CA3088401A1 (da)
CY (1) CY1123203T1 (da)
DK (2) DK3744326T3 (da)
EA (1) EA037185B1 (da)
ES (2) ES2967585T3 (da)
FI (1) FI3744326T3 (da)
HR (2) HRP20240022T1 (da)
HU (2) HUE049485T2 (da)
IL (3) IL254669B2 (da)
LT (2) LT3744326T (da)
MA (1) MA41917B1 (da)
MD (2) MD3280416T2 (da)
NZ (1) NZ735952A (da)
PL (2) PL3744326T3 (da)
PT (2) PT3280416T (da)
RS (2) RS60510B1 (da)
SI (2) SI3280416T1 (da)
SM (2) SMT202000351T1 (da)
TW (1) TWI694825B (da)
UA (1) UA118732C2 (da)
WO (1) WO2016164218A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3744326T3 (fi) 2015-04-07 2024-02-02 Janssen Pharmaceutica Nv Annosteluohjelma pitkävaikutteisten injektoitavien paliperidoniestereiden ottamatta jääneille annoksille
AU2018354431B2 (en) 2017-10-27 2024-01-18 Geneora Pharma (Shijiazhuang) Co., Ltd. Dosage regimen of paliperidone palmitate extended-release injectable suspension
MX2023006370A (es) * 2020-11-30 2023-08-07 Janssen Pharmaceutica Nv Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
SMT202400077T1 (it) * 2020-11-30 2024-03-13 Janssen Pharmaceutica Nv Regimi di dosaggio associati con formulazioni iniettabili di paliperidone a rilascio prolungato
CA3203015A1 (en) * 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
CN116528837B (zh) 2020-11-30 2025-03-14 詹森药业有限公司 用于确保棕榈酸帕潘立酮制剂再悬浮的方法
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.
AU2022337993A1 (en) * 2021-08-30 2024-04-11 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
KR102869809B1 (ko) 2023-11-21 2025-10-13 주식회사 엘지에너지솔루션 양극 및 이를 포함하는 전고체 전지

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
JP5249748B2 (ja) 2005-04-25 2013-07-31 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 無菌３−［２−［４−（６−フルオロ−１，２−ベンズイソオキサゾール−３−イル）−１−ピペリジニル］エチル］−６，７，８，９−テトラヒドロ−９−ヒドロキシ−２−メチル−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンパルミチン酸エステルの製造
CN101932327A (zh) * 2007-12-19 2010-12-29 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
WO2011042453A1 (en) * 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
KR20120116401A (ko) 2009-10-30 2012-10-22 얀센 파마슈티카 엔.브이. 장기-작용성의 주사가능한 팔리페리돈 에스테르와 관련된 투약 요법
EP2529757B1 (en) * 2011-05-31 2014-01-08 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation
FI3744326T3 (fi) 2015-04-07 2024-02-02 Janssen Pharmaceutica Nv Annosteluohjelma pitkävaikutteisten injektoitavien paliperidoniestereiden ottamatta jääneille annoksille

Also Published As

Publication number Publication date
RS65024B1 (sr) 2024-01-31
IL254669B2 (en) 2024-05-01
PL3744326T3 (pl) 2024-03-25
KR102606678B1 (ko) 2023-11-24
AU2016244801A1 (en) 2017-10-05
PT3744326T (pt) 2024-01-15
EP3280416B1 (en) 2020-04-22
JP7422277B2 (ja) 2024-01-26
EP4349323A2 (en) 2024-04-10
SMT202000351T1 (it) 2020-09-10
KR20170134583A (ko) 2017-12-06
EP3280416A1 (en) 2018-02-14
ES2967585T3 (es) 2024-05-03
TWI694825B (zh) 2020-06-01
UA118732C2 (uk) 2019-02-25
FI3744326T3 (fi) 2024-02-02
PL3280416T3 (pl) 2020-12-14
AU2020239611A1 (en) 2020-10-15
CA2925908A1 (en) 2016-10-07
US20170281629A1 (en) 2017-10-05
HRP20201027T1 (hr) 2020-12-11
DK3744326T3 (da) 2024-02-05
CA3088401A1 (en) 2016-10-07
NZ758246A (en) 2024-05-31
SI3744326T1 (sl) 2024-02-29
KR20230162162A (ko) 2023-11-28
JP7228503B2 (ja) 2023-02-24
EP3744326B1 (en) 2023-12-06
CY1123203T1 (el) 2021-10-29
SMT202300478T1 (it) 2024-01-10
AU2016244801B2 (en) 2020-06-25
AU2024227790A1 (en) 2024-11-21
TW201642863A (zh) 2016-12-16
IL309340A (en) 2024-02-01
JP6728221B2 (ja) 2020-07-22
IL254669A0 (en) 2017-11-30
IL324059A (en) 2025-12-01
IL254669B1 (en) 2024-01-01
LT3280416T (lt) 2020-06-25
JP2020090498A (ja) 2020-06-11
MD3744326T2 (ro) 2024-05-31
HUE049485T2 (hu) 2020-09-28
EP3744326A1 (en) 2020-12-02
IL309340B1 (en) 2026-01-01
HUE065435T2 (hu) 2024-05-28
PT3280416T (pt) 2020-06-30
JP2021130680A (ja) 2021-09-09
WO2016164218A1 (en) 2016-10-13
SI3280416T1 (sl) 2020-07-31
MA41917B1 (fr) 2020-07-29
ES2802299T3 (es) 2021-01-18
EA201792209A1 (ru) 2018-02-28
AU2020239611B2 (en) 2022-07-21
JP2018510894A (ja) 2018-04-19
US10143693B2 (en) 2018-12-04
HK1249047A1 (en) 2018-10-26
NZ735952A (en) 2022-02-25
KR20250013293A (ko) 2025-01-31
KR102755145B1 (ko) 2025-01-14
LT3744326T (lt) 2023-12-27
MD3280416T2 (ro) 2020-10-31
EA037185B1 (ru) 2021-02-17
HRP20240022T1 (hr) 2024-03-29
CA2925908C (en) 2020-09-01
EP3280416A4 (en) 2019-01-23
AU2022221405A1 (en) 2022-09-15
EP4349323A3 (en) 2024-06-12
BR112017021383A2 (pt) 2018-07-03
AU2022221405B2 (en) 2024-08-01
RS60510B1 (sr) 2020-08-31

Similar Documents

Publication Publication Date Title
EP3754089C0 (de) Dosiereinrichtung
HUE048644T2 (hu) Adagoló rendszer
DK3310231T3 (da) Doseringsindretning
PL3131533T3 (pl) Doustna postać dawkowania ketaminy
HUE043290T2 (hu) Adagoló kapszula
DK3325051T3 (da) Variabel enkeltdosisinjektor
DK3220892T3 (da) Langtidsvirkende væksthormondoseringsformer
DK3253485T3 (da) No-holdige sammensætninger
IL258525A (en) Dosing regimens
ES1162584Y (es) Aparato dosificador
IL259101A (en) Melflufen dosage regimens for cancer
PL3609808T3 (pl) Pojemnik dozujący
HUE049494T2 (hu) Vetõmag adagolás
EP3600836A4 (en) ENERGY DOSAGE FOR ADDITIVE MANUFACTURING
PT3126791T (pt) Dispositivo doseador
FR3030466B3 (fr) Valve doseuse multilame
HUE065920T2 (hu) Kupakok referenciás adagolása
EP3810063A4 (en) Individual dose pack
IL269169A (en) Novel dosage form
DE112015005590A5 (de) Dosierpumpe
ITUB20152349A1 (it) Metodo di dosaggio autocalibrato
DK3288967T3 (da) Farmaceutisk forbindelse
PL3215437T3 (pl) Urządzenie dozujące
EP3441975C0 (en) DOSING UNIT RECHARGE SCHEDULE
EP3369339C0 (en) DOSING CONTAINER